<SEC-DOCUMENT>0001104659-25-098882.txt : 20251014
<SEC-HEADER>0001104659-25-098882.hdr.sgml : 20251014
<ACCEPTANCE-DATETIME>20251014060616
ACCESSION NUMBER:		0001104659-25-098882
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251013
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251014
DATE AS OF CHANGE:		20251014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		251389258

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2528558d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:syn="http://syntheticbiologics.com/20251013">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_syn_syntheticbiologics.com_20251013 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20251013_20251013 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000004" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20251013.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-13</xbrli:startDate>
        <xbrli:endDate>2025-10-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20251013__20251013_zX3p2ugruwpa"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_908_edei--DocumentPeriodEndDate_c20251013__20251013_zrRnvTgjbHf2"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 13, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20251013__20251013_zjshcLVIshC3"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000011" name="dei:EntityRegistrantName">THERIVA BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20251013__20251013_z0ym45EFgSsg"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20251013__20251013_zO3IA2qvNTae"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000013" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20251013__20251013_zbNYc72sAHue"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 0.8pt">(State or other jurisdiction of<br/>
incorporation)</td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="text-align: center; padding-right: 0.8pt">(IRS Employer Identification<br/>
No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20251013__20251013_zg0GQgqpL4hf"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000015" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20251013__20251013_z6rhFczroA56"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20251013__20251013_z1OCU1jlOECj"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000017" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20251013__20251013_zqZwZaVvE6Il"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20251013__20251013_z3IVOynNS4c7"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000019" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_909_edei--CityAreaCode_c20251013__20251013_zaNHX10sqUo9"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000020" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_90A_edei--LocalPhoneNumber_c20251013__20251013_zDqCrbDihAaf"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000021" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font: 10pt Wingdings"><span id="xdx_908_edei--WrittenCommunications_c20251013__20251013_zE4laYUUEsx5"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Wingdings"><span id="xdx_906_edei--SolicitingMaterial_c20251013__20251013_zaaj64fWrHIk"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20251013__20251013_zwoKW2jRqjHd"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Wingdings"><span id="xdx_901_edei--PreCommencementIssuerTenderOffer_c20251013__20251013_zaABk8OfDdNd"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on<br/>
 which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20251013__20251013_zreFuzhROX7c"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000026" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20251013__20251013_zmJIpwi3vrWg"><ix:nonNumeric contextRef="AsOf2025-10-13" id="Fact000027" name="dei:TradingSymbol">TOVX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20251013__20251013_zZtHF405Y372"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20251013__20251013_zmR4RXsl1KLk"><ix:nonNumeric contextRef="AsOf2025-10-13" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01. Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 13,
2025, Theriva Biologics, Inc. (the &#8220;Company&#8221;) issued a press release announcing the presentation on October 20, 2025 of
expanded metastatic pancreatic ductal adenocarcinoma (mPDAC) data from the VIRAGE Phase 2b trial (NCT05673811) at the European
Society for Medical Oncology (ESMO 2025) Annual Congress. The press release also announced a separate poster presentation on the
same day describing previously reported data for SYN-004 (ribaxamase) in allogeneic hematopoietic transplant recipients at
Infectious Diseases Week (IDWeek) 2025 Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results from the VIRAGE Phase 2b trial included in the abstract are
set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">112 patients were randomized. Patients in the
modified intent to treat (mITT) population received at least 1 dose of gemcitabine/nab-paclitaxel (GA) standard of care chemotherapy (GA,
Arm I) or VCN-01 (Arm II). Patients in the full analysis set (FAS) population received at least 1 dose of gemcitabine/nab-paclitaxel standard
of care chemotherapy (GA; Arm I) or VCN-01 followed by at least 1 dose of GA (Arm II).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mITT</span></td>
    <td colspan="3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAS</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt; width: 6%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    I (48)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    II (53)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; width: 19%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR
    (95% CI)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    I (48)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    II (48)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; width: 23%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR
    (95% CI)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">OS</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">mo.</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.69
                                            (0.42-1.12)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.196</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.8</span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.57
                                            (0.34-0.96)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.055</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">PS</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">mo.</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.63
                                            (0.4-1.0)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.047</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7.0</span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.55
                                            (0.34-0.88)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.011</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">DoR</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">mo.</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.4</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11.2</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.22
                                            (0.08-0.62)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.004</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.4</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11.2</span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.22
                                            (0.08-0.62)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.004</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORR</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3%</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.8%</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3%</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.6%</span></td>
    <td style="border: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="7" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 3pt; text-align: left; padding-top: 4pt; padding-bottom: 4pt; font-size: 10pt">Definitions -mo. (Months). OS (overall survival). PS or PFS (progression
free survival). DoR (duration of response). ORR (objective response rate). HR (hazard ratio). CI (confidence interval). </td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compared to patients who started GA cycle 4 alone
(Arm I), patients who received 2 VCN-01 doses and started GA cycle 4 (Arm II) showed greater improvement in OS (14.8 vs 11.6 months;
HR 0.44; 95% CI 0.21 - 0.92; <i>P</i>=0.046) and PFS (11.2 vs 7.4 months; HR 0.48; 95% CI 0.25 - 0.91; <i>P</i>=0.017). VCN-01 administration
was well tolerated. All VCN- 01-related serious adverse events (n=13) were resolved, the most common being flu-like symptoms (13,2%),
transaminase increase (5.7%) and drug-induced liver injury (3.8%). Viral genome analysis confirmed the bioactivity of the second VCN-01
dose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This study met its primary endpoints. Patients receiving VCN-01 + GA
had improved OS, PFS and DoR compared to GA standard of care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The full
abstract for the presentation has been&#160;released by ESMO.&#160;</span>A copy of the abstract titled &#8220;VIRAGE trial: randomized
Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic
Cancer (mPDAC )&#8221; is filed as an exhibit to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information in this
Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The press release furnished
as Exhibit 99. to this Current Report on Form 8-K includes &#8220;safe harbor&#8221; language pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, indicating that certain statements contained therein are &#8220;forward-looking&#8221; rather than historical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01. Other Events.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2025, the Company issued a press
release announcing the presentation on October 20, 2025 of expanded metastatic pancreatic ductal adenocarcinoma (mPDAC) data from the
VIRAGE Phase 2b trial (NCT05673811) at ESMO 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results from the abstract for the VIRAGE Phase 2b trial are set forth
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">112 patients were randomized. Patients in the
modified intent to treat (mITT) population received at least 1 dose of GA (Arm I) or VCN-01 (Arm II). Patients in the full analysis set
(FAS) population received at least 1 dose of gemcitabine/nab-paclitaxel standard of care chemotherapy (GA; Arm I) or VCN-01 followed
by at least 1 dose of GA (Arm II).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mITT</span></td>
    <td colspan="3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAS</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt; width: 6%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    I (48)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    II (53)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; width: 19%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR
    (95% CI)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    I (48)</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; width: 13%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    II (48)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; width: 23%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR
    (95% CI)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">OS</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">mo.</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.69
                                            (0.42-1.12)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.196</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.8</span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.57
                                            (0.34-0.96)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.055</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">PS</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">mo.</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.63
                                            (0.4-1.0)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.047</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.6</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7.0</span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.55
                                            (0.34-0.88)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.011</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">DoR</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">mo.</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.4</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11.2</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.22
                                            (0.08-0.62)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.004</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.4</span></p></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11.2</span></p></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">0.22
                                            (0.08-0.62)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>P</i>=0.004</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 4pt; padding-bottom: 4pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORR</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3%</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.8%</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3%</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.6%</span></td>
    <td style="border: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="7" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 3pt; text-align: left; padding-top: 4pt; padding-bottom: 4pt; font-size: 10pt">Definitions: mo.(months). OS (overall survival). PS or PFS (progression
free survival). DoR (duration of response). ORR (objective response rate). HR (hazard ratio). CI (confidence interval)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compared to patients who started GA cycle 4 alone
(Arm I), patients who received 2 VCN-01 doses and started GA cycle 4 (Arm II) showed greater improvement in OS (14.8 vs 11.6 months;
HR 0.44; 95% CI 0.21 - 0.92; <i>P</i>=0.046) and PFS (11.2 vs 7.4 months; HR 0.48; 95% CI 0.25 - 0.91; <i>P</i>=0.017). VCN-01 administration
was well tolerated. All VCN- 01-related serious adverse events (n=13) were resolved, the most common being flu-like symptoms (13,2%),
transaminase increase (5.7%) and drug-induced liver injury (3.8%). Viral genome analysis confirmed the bioactivity of the second VCN-01
dose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The study met its primary endpoints. Patients receiving VCN-01 + GA
had improved OS, PFS and DoR compared to GA standard of care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full abstract for the presentation has been
released by ESMO. A copy of the abstract titled &#8220;VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine
with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC ).&#8221; is filed as an exhibit to this Current
Report on Form 8-K. and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The expanded data will be presented at ESMO
2025 on October 20, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26.2pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;</span></td>
    <td style="width: 96%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><a href="tm2528558d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><a href="tm2528558d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release issued by Theriva Biologics, Inc., dated October 13, 2025</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><a href="tm2528558d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify; vertical-align: top; padding-right: 0.8pt"><a href="tm2528558d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstract:
    &#8220;VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in
    Patients with Metastatic Pancreatic Cancer (mPDAC)&#8221;</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: October 14, 2025</span></td>
    <td colspan="3" style="padding-right: 2.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERIVA
    BIOLOGICS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 0.9pt">&#160;</td>
    <td style="width: 3%; padding-right: 0.9pt">&#160;</td>
    <td style="width: 5%; padding-right: 0.9pt">&#160;</td>
    <td style="width: 42%; padding-right: 0.9pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.9pt">&#160;</td>
    <td style="padding-right: 0.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.9pt">&#160;</td>
    <td style="padding-right: 0.9pt">&#160;</td>
    <td style="padding-right: 0.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="padding-right: 0.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.9pt">&#160;</td>
    <td style="padding-right: 0.9pt">&#160;</td>
    <td style="padding-right: 0.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<br/>
    and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZS02j3XRpURGrSBFxG+0owTZTJrHqkbylsUUcBobh//e/ECOxpIWpkeE4KwvYY9PW2iOUeEFGe8bgyFfrDMIt8WqcZ219//7AnAKDgUljpU5B6K2dcVhlINNxko7VFOQkSyTsNiL66jnZi6nQeqNr0LaCHVPLBr3m15Cw10+y1Lz6qgOyM2QzSGI5yG9QMlGwpU4/iG8OiiIX0aifSCyZ7m1wzZ8e7ZeEeY1NqHMD/d/oAwQMSog= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2528558d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm2528558d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva&trade; Biologics Announces Upcoming
Presentations at Medical Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- VCN-01 expanded mPDAC data from VIRAGE Phase
2b trial to be presented at ESMO 2025 -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- SYN-004 Interim blinded safety and pharmacokinetic
data to be presented at IDWeek 2025 -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rockville, MD, October 13, 2025 &ndash;</B> Theriva&trade; Biologics
(NYSE American: TOVX), (&ldquo;Theriva&rdquo; or the &ldquo;Company&rdquo;), a diversified clinical-stage company developing therapeutics
designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European Society
for Medical Oncology (ESMO 2025) Annual Congress and at Infectious Diseases Week (IDWeek) 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>VCN-01 upcoming mini-oral presentation at ESMO 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Expanded data from the VIRAGE trial investigating VCN-01 (zabilugene
almadenorepvec) are to be presented at a mini oral session at the ESMO 2025 Congress:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Presenting author: Dr. Roc&iacute;o Garcia-Carbonero, Hospital 12 de Octubre,
Madrid, Spain</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel
and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Abstract #: 2216MO</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date and time: Monday, October 20, 2025, 09:28 a.m. CEST</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Session: Mini oral session 2, GI Tumors Upper digestive</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Location: Bonn Auditorium - Hall 7.1c, Messe Berlin, Berlin, Germany</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SYN-004 upcoming poster presentation at IDWeek 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Previously disclosed blinded safety and pharmacokinetic (PK) data from
the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic
cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). These data will be presented at ID Week
2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presenting Author: Erik R. Dubberke, MD, Professor of Medicine, Clinical
Director, Transplant Infectious Diseases, Washington University School of Medicine in St. Louis</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Title: Safety and tolerability of SYN-004 in allogeneic haematopoietic cell transplant (HCT) recipients
receiving meropenem (MER) or piperacillin/tazobactam (P/T)</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Abstract #: P-104</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Date and time: Monday, October 20, 2025 from 12:15 to 1:30 p.m US EDT</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Location: Poster Hall B4-5, Georgia World Congress Center, Atlanta, Georgia</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="tm2528558d1_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About VCN-01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic
adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant
physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects
by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products;
and (iii) increasing tumor immunogenicity and exposing the tumor to the patient&rsquo;s immune system and co-administered immunotherapy
products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered
to 142 patients to date in clinical trials of different cancers, including pancreatic ductal adenocarcinoma (in combination with chemotherapy),
head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer,
and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About SYN-004 (ribaxamase)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade
certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of Clostridioides
difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease
(aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam
antibiotics to treat infection following conditioning therapy. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients
may lead to adverse outcomes including CDI, VRE colonization and potentially fatal bacteremia and aGVHD. A previously completed placebo-controlled
Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients
who received SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences
of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Theriva&trade; Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva&trade; Biologics (NYSE American: TOVX), is a diversified clinical-stage
company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company&rsquo;s subsidiary
Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral
delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained
anti-tumor response by the patient&rsquo;s immune system. The Company&rsquo;s lead clinical-stage candidates are: (1) VCN-01 (zabilugene
almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor
stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which
is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome
damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence
and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020,
a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat
both local GI and systemic diseases. For more information, please visit Theriva Biologics&rsquo; website at <U>www.therivabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:<BR>
Kevin Gardner<BR>
LifeSci Advisors, LLC<BR>
kgardner@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm2528558d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abstract 5555</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 4pt 0pt 0">VIRAGE trial: randomized
Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic
Cancer (mPDAC)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 405pt 0pt 0">Type: Abstract Category: Pancreatic cancer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">Authors:</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>R. Garcia-Carbonero</U><SUP>1</SUP>, R. Pazo Cid<SUP>2</SUP>, T. Macarulla
Mercade<SUP>3</SUP>, B. Laquente<SUP>4</SUP>, A. Nguyen<SUP>5</SUP>, C. Guillen Ponce<SUP>6</SUP>, A. Munoz Martin<SUP>7</SUP>, E. Kim
<SUP>8</SUP>, M. Cazorla<SUP>9</SUP>, T. Seery<SUP>10</SUP>, M. Lobo de Mena<SUP>11</SUP>, C. Nevala-plagemann<SUP>12</SUP>, V. Sharma<SUP>13</SUP>,
E. Martinez de Castro<SUP>14</SUP>, C. Le<SUP>15</SUP>, M. Kaleko<SUP>16</SUP>, M.A. Shallcross<SUP>17</SUP>, C. Blasco<SUP>18</SUP>,
M. Cascallo Piqueras<SUP>19</SUP>, M. Hidalgo<SUP>20</SUP>; <SUP>1</SUP>Medical Oncology Department, Hospital Universitario 12 de Octubre
Imas12, UCM, Madrid, Spain, <SUP>2</SUP>Medical Oncology Department, HospItal Universitario Miguel Servet, Zaragoza, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>3</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology Dept., VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>4</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology Department, ICO - Institut Catal&agrave; d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet De Llobregat, Spain,
</FONT><FONT STYLE="font-size: 14pt"><SUP>5</SUP></FONT><FONT STYLE="font-size: 10pt">Internal Medicine, Weill Cornell Medicine - Gastrointestinal
(GI) Oncology, New York, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>6</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>7</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>8</SUP></FONT><FONT STYLE="font-size: 10pt">UC
Davis School of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>9</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology, HUVV - Hospital Universitario Virgen de la Victoria, Malaga, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>10</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology Department, Hospital Universitario 12 de Octubre Imas12, UCM, Newport Beach, Ca, AL, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>11</SUP></FONT><FONT STYLE="font-size: 10pt">Medical
Oncology Department, CHGUV - Consorcio Hospital General Universitario de Valencia, Valencia, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>12</SUP></FONT><FONT STYLE="font-size: 10pt">Oncology,
University of Utah Health - Huntsman Cancer Institute, Salt Lake City, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>13</SUP></FONT><FONT STYLE="font-size: 10pt">Medicine,
University of Louisville, Louisville, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>14</SUP></FONT><FONT STYLE="font-size: 10pt">Oncologist,
HUMV - Hospital Universitario Marques de Valdecilla, Santander, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>15</SUP></FONT><FONT STYLE="font-size: 10pt">Departments
of Biometrics, Theriva Biologics, Inc., Rockville, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>16</SUP></FONT><FONT STYLE="font-size: 10pt">Research
and Development Dept., Theriva Biologics, Inc., Rockville, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>17</SUP></FONT><FONT STYLE="font-size: 10pt">Clinical
Operations, Theriva Biologics, Inc., Rockville, United States of America, </FONT><FONT STYLE="font-size: 14pt"><SUP>18</SUP></FONT><FONT STYLE="font-size: 10pt">Clinical
Operations, Theriva Biologics SL, Parets Del Valles (Barcelona)Barcelona, Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>19</SUP></FONT><FONT STYLE="font-size: 10pt">Management,
Theriva Biologics SL, Parets Del Valles (Barcelona), Spain, </FONT><FONT STYLE="font-size: 14pt"><SUP>20</SUP></FONT><FONT STYLE="font-size: 10pt">Hematology
Oncology Department, NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, United States of America</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0">VCN-01 (zabilugene almadenorepvec) is an oncolytic
adenovirus expressing hyaluronidase to degrade tumor stroma, facilitate chemotherapy and enhance the antitumor immune response. Building
on an acceptable safety profile and encouraging activity when combined with standard of care (SoC) gemcitabine/nab-paclitaxel (GA), we
conducted an open-label, controlled, randomized phase IIb trial to evaluate the efficacy and safety of two doses of VCN-01 with GA in
mPDAC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Methods</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chemona&iuml;ve mPDAC patients were randomized 1:1
to receive SoC doses of GA on days 1, 8 and 15 of repeated 28-<FONT STYLE="font-size: 10pt">day cycles (Arm I) or 2 separate IV doses
of VCN-01 (1x10</FONT><FONT STYLE="font-size: 14pt"><SUP>13</SUP></FONT> <FONT STYLE="font-size: 10pt">vp/dose) 1 week prior to each of
cycle 1 &amp; 4 of GA (Arm II). Primary endpoints were overall survival (OS) and safety. The trial was designed with 80% power to detect
OS differences with 2-sided alpha 0.1 in mITT or FAS populations. Secondary objectives included PFS, response rates, duration of response
(DoR) and biomarker Ca19.9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">112 patients were randomized. Patients in the mITT
population received at least 1 dose of GA (Arm I) or VCN-01 (Arm II). Patients in the FAS population received at least 1 dose of GA (Arm
I) or VCN-01 followed by at least 1 dose of GA (Arm II).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mITT</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; width: 6%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; width: 13%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    I (48)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; width: 13%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    II (53)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; width: 19%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR
    (95% CI)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; width: 13%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    I (48)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; width: 13%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arm
    II (48)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; width: 23%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR
    (95% CI)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt">OS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.65pt">mo.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-align: center">8.6</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.4pt; text-align: center">10.6</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">0.69
    (0.42-1.12)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>P</I>=0.196</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt; text-align: center">8.6</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt; text-align: center">10.8</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">0.57
    (0.34-0.96)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>P</I>=0.055</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.65pt">PS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.65pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.65pt">mo.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-align: center">4.6</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-align: center">5.6</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">0.63
    (0.4-1.0)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>P</I>=0.047</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt; text-align: center">4.6</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt; text-align: center">7.0</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">0.55
    (0.34-0.88)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>P</I>=0.011</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt">DoR</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.65pt">mo.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-align: center">5.4</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.4pt; text-align: center">11.2</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">0.22
    (0.08-0.62)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>P</I>=0.004</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt; text-align: center">5.4</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt; text-align: center">11.2</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">0.22
    (0.08-0.62)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>P</I>=0.004</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORR</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3%</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.8%</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3%</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.6%</FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding: 4pt; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mo.
    months</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0">Compared to patients who started GA cycle
4 alone (Arm I), patients who received 2 VCN-01 doses and started GA cycle 4 (Arm II) showed greater improvement in OS (14.8 vs 11.6
months; HR 0.44; 95% CI 0.21 - 0.92; <I>P</I>=0.046) and PFS (11.2 vs 7.4 months; HR 0.48; 95% CI 0.25 - 0.91; <I>P</I>=0.017). VCN-01
administration was well tolerated. All VCN-01-related serious adverse events (n=13) were resolved, the most common being flu-like symptoms
(13,2%), transaminase increase (5.7%) and drug-induced liver injury (3.8%). Viral genome analysis confirmed the bioactivity of the second
VCN-01 dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This study met its primary endpoints. Patients receiving
VCN-01 + GA had improved OS, PFS and DoR compared to GA SoC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical trial identification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NCT05673811</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Editorial acknowledgement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>syn-20251013.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaCDCbOdzZR+qYkxtmB3bQn6jyUrOZaZmCwoV7U20b8I -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:syn="http://syntheticbiologics.com/20251013" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20251013">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20251013_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20251013_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>syn-20251013_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>syn-20251013_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="syn-20251013.xsd#Cover" roleURI="http://syntheticbiologics.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2528558d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2528558d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ /T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBHIYXK
M:!YII4CC099W; 4>I- $F11D>M>2>)_C1;P+):^'8//E!*FZG&$'NJ]6^IP/
MK7#Z7\4_%.GZ@]S+>_;$D;<\,X&P_P"[C&W\.*]*GEF(G'FM;U.66*IIVW/I
M3-)D>M<?X3^(NC^*\01L;6_VY:VF/7_=/1OY^U9GQ!U3Q18*ILP(-./!GMR2
M^?\ :/\ #^'YUA2P=2I65%VB_/0NI7C"G[1:KR/0\CUI:\F\/_%&>#R[;6HC
M,@X^TQC# >Z]#^'ZUZA97UMJ%LEQ:3QS0N,AD.13Q6"KX65JJ^?1BH8FG65X
M,LT4TNJ_>8#ZFD\V/_GHOYUR69T7'T4SS8_^>B_G1YL?_/1?SHLQ70^BF/+'
M'C>ZKGU.*<K*ZAE8$'N#2L,6BBB@ HHHH **** "BBB@ HJ-IX5E6)I4$C#(
M0L,G\*DH **** "BBB@ HHHH **3(]:6@!#7S9\1=9U74_&6H:=->326T-P8
MH;<-A!@\<=,^YKZ3-?,?C 8^)FI?]?P_F*]?*4O:R;6R.+&-\J]3K='^&FG^
M'XDU'QC<H^?]590DG<W4AB,9^@X]ZWI-2\(:U"-+O]"CM[-?EMWB0 QY[_+R
MO/IFKOQ5!^R:9CJ)'/Z+1\-M-M;C39=1GA62ZCN"B.W.T!5/'OR>:ZG)2POU
MJLVW>RL[6]#RISK?7/JU%I16]U>YYYXF^%NLZ$TE]I1:^L5.]&BSYT8ZY*]\
M>J_D*L>$_BSJ&DM]DUWS=1LR,!S@RQ_B?O#V/YUVZ^-=0.O!=R_8S-L\OR^=
MN<9]<_C6EXB^&>@>(;M+QH7M;@ONE>V8)Y@[Y&",^_!]Z\W"YQ0QD73KJZ77
MK_7F=&&JTZ[E+#/9V:_KH8&I^'/#OBK2)];\-744;QJ7EB7A>!D@KU0_I_.L
M[X42S_\ "4W$>]A$;1F* \$AEP2/7DUT.K:WX;\(:)<Z%HZ()BC(8XE+ ,1@
MEVSR?Q)XKGOA5_R-<W_7F_\ Z$E>Y3=:67UO:7Y?LWWMH3-4UBH<F_6QO?$S
MP/JWBZ\T^737ME6W1U?SG*\D@C& ?2O.M3^$WB+2=,NM0N9+ PVT32N$F8G
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MK&GFTG)VT_&R'MJ?@= -:65FDW;Q:C.[?U^Y]>^<5RNO?$+6-8S% _V&V/\
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DJ3R<UMT5*J22:7]7W^\J5"$I*36UOPVT\A , "EHHK,V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 13,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERIVA BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TOVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2528558d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>syn-20251013.xsd</File>
    <File>syn-20251013_lab.xml</File>
    <File>syn-20251013_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2528558d1_8k.htm">tm2528558d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2528558d1_8k.htm": {
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20251013",
   "dts": {
    "schema": {
     "local": [
      "syn-20251013.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20251013_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20251013_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2528558d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://syntheticbiologics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2528558d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2528558d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-098882-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-098882-xbrl.zip
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MY3C]=_+<>2)N%WO!PVK8"DE#&1XJ-GM]P*@8)()\G%B7N,H;&M97R8QR=Z\
M6VP=7@&N%08!@<U1^Q5@=?5$B5QWLV24$PR,",UB9YUL,57U<:TLC"YN&VKU
M</&]%AH?7V29W26]>V04?D"@+7'5TY YW=MF>1 ]#I@R>[V0H4+GZ6J\S#"1
MV8?O6IFSF=VT4TWDNB"(WC7=M*9I7>ZX-W_C22[V/&.;S9:6=WELSPT".E>]
MW&E3][A5%$3O=SDS22BUJ"EVC,6"I4F4Y E=_RI./GF";:VRB5P! 1O4-+05
M0:  VC(Y. B15CJ&X(X3"2$1'5&\!"@3"_';AP?K;-\E=@5%OV$-!ZP, I)>
M>R8L(F <U2*0"D%%C%]LYEFV)?Q-\%A"/"$$F@= :NE#Q DRV0N5"O3)UH)$
M6S$_[H^GJV62I[:3R[;$V9P$F*MF)*,\"#8 4R8+11EB#^AX^K?5WY&.<MS]
M-VS)L<P=N]AO5BP%LD]95:X@Z+"H.;!(@D !]F72<,-0*45*ZR,[5<.LI3E&
MN2L K+9TUS<*@^ATFZ/6E[_1UYZ&_,M=]"A,$>"%!+O,]=!O,VD._W5-$ AT
M&&N=E)12I+4^7D@X3%GK_D7 VMLB8-VS"%B'N A8#UT$K+TM O1N58H0,2[=
MKM)DC8'DA)UJUU!T6#;YL$B#0@7V!XX950@ZQ+C.:%FD.)/I^?FFV/^5^&!I
M):!SEM.RRV:5U-(F"H*1+F>MM)8JZ5Q-C*3:-1?;.,E)K,Q<)133*,%IE1[1
M=D6\/\09+0/-5^#TZ,-@:)C)%DXJ3.<RK (/J2Y=7TI7#V#\1M+T%\I>Z8+@
MC%$2JVLIMCM%W7JW3\STV&X^- .(@\!IB$/@T1D9-'Z244B'E5?"O)#TC:5;
MFF->O$O.;2,3H'-+#F"S28PA"H@4NS. D$J,E-K/"]HJ>T2UR%*_.P0V$)([
M?EV[T[3QUK95&Q SG0:A=[C+G!^'M;&*\O2*94[D[T4D+^0+SG'I#6PO)'?]
M4F67:?-M2ILV((0Z#8+O3U8Q,E4,UDQY2QG#9V*IM68=3XD;*O>)8UH6V[EC
M*DE >-A\=620X4AKO;"PV. T_;S-$DHR>"(R5&Y9L%ILLM"0!,2"S1? 0B%%
M6NN%A<L-X6LQO?W,V6O^6.9G!=L&J-VRT6FYR8A5&A K7?X 9G0(4C$ZI:X?
M>':'A.(JRR+<4HO4,3:@68.9EBXD8"!S+5I2$LGK+3<L1TN&OF8$Y8\$798_
M0U?/!*_J\?5+(U$D7XA0JW(:8VY#J$OL_%='0,.MWQYI*8, J=<>_#LD5032
M(8ZIN14,\_IY7&%BGI,-^+9#?X@K@H::UQSUZ8.@::!)DZDBK'ER700B&>DS
MFU$]N3V\Q&N('*^,+0:-A7%-$00CH"UH65S_K0 _N?.VJS2)KE*&X:LL#8WC
MC'EM>T:RO(,@( +:KJ 4>840%4HO_?\9TR>^?<ZC_1UG$2'R*:NL&JWZKK\-
MC';+S)N:U*1I4&A G+W%+T#@H0I4J^-#;<;R>3%//C0NL[FQZ&GQB,4!O-WF
MF9Q!A3'X*GAGD./;"P,:8-QDZ(@("+T!-J$;#D4D*D(_(!6,:M&>SL^R0Q9
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MET=%MOM(!?<I/M6SHYM N-OS6!6E>R+ [):N*O(A\2[ZX[C7^<EU7%K*4O[
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M'P-2 ZN&HD5DVE4T[^$_S:O(<'DR_RCQY GB[#@@Q?7N'[+BC-]'80\0&O@
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M%)*,!J8LF-3A4/OIG#\2<4<J!D?*NR/QTR/Q^R!J;VVB/ "51> N5*W8HXB
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M_XO6Z$^^\?O\\B0C9_3*X]?+MM[[['(DT]'E$?[MVP.U_/]02P,$%     @
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M"Q7=$')[?,%_L!6?#?J@0>])QO?-^H"QQ\H$<N\&4(#8 $N EY\0[K:2H\'
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MC5J,LV/Y#6(DXY5=$; _<O3QXRFT#LA(-"8+Y1U]O6Z 2CI1OM(*,E8K'+;
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M-+AB!G,#*5DV<\5=@YD\;+*7-#G5H,7^%Z!91S?*R8VZ!M?#8,+M\'(EN=Q
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M+!G^,'P4.B-A8S![CKM)PN;KV>]<R("YB(%(=)3KPREGQ@@C'C)0;ZU'"4G
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MY7)GS(U=P+P3M:W(+B;ANE]X=RS<P /^!?-1SQ/V$$83)@.<3.)\W>/@4_J
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M%+5PA\1J]GHDV$_U+O;B!#)*1&@IE[P!4:OZGSDY'.Q'V(8,J(_VIVYNZLJ
M](&&9091&A,I.KJ7S>R<J4[$31]S7N;>TUR?Z8?:H38-F.\8ZDE7_\KGX9/@
MTJ0]EB$_QO:T"&^0>4 ^GVPRG*%9SFT-1GL7>FG!YL4^7>LK%Z<?TVNG$@,R
MZ#BXIZ0PD8!OMQK)&&>,U@HXYH+A<7K/[O-]/L (>(1 )IK3).TOH(C(7'7(
ME& *))E(&.]4FZ<TKPFDO\1QOW,?K>NEI1Y9FVUV(JPI^A*TLYD9J!-?C1[
M!\F9YZ/EDD>;\U.AFTW<Z<QS?=7WO+MX2L_9S%S7 \PFT&FA4YA\EQP<_)=P
M#[/-T/3FY]>;H_56\^+ZXU;C_+IWWGG^WFB5MD9CQX'IK&2.AQ!/OD4;GBMO
MBL;]A;[A*R\T'4SR@;_@KL-,2F2/:-L_,N^YP)E(O7>6&K5Q0Y)"8>QMK9V"
M-.J,</JV@*IO@_V 64).CGZDA&]Z(J"EYWXO9C)\ >77D@$ZA&^FOS_7#&.L
M[&\_U2)?B0!];_O-M1'Z6^*K"3OEZNYBX_PM^46&*WMOQ/ B)A,A'"XRN_4Q
M?-F)V-HYK&Q#H[E)&MY BUX'PZ\54V(9E?9^GL'_]&"3GC(],Y6,7O'3]BOA
MOE8WRBM#:M?:<SH!7E_OI;AW2VG1]/ 54;D&6;^6&'2M7%D,DZV3JK:_X:)9
M)AF]^ :B63ST2U]]3GS@D]Y2138/8Q]6U,JEO*[II=V7R?G9M*Q#R<\>O-8\
M:=<*S9./14T_W'!45/_XBU4E@_ZB^C+1O$XJ].;NI'(P=2=[Y7Q1.]S?='=2
MC,ID?J^DL!(G5^VU)X65/TGASTT*RYONY)>+IK(Q2>'>+"G$G+"X\3Z\?+#9
MF%B:^&R\MU@JF0.M^"<CI(RP,I\15JL;[TVH\.!WRPAU+4RLSE1G_1C[DQ#^
MW*RGO.&B63KKU^D$ADU("$NEJ1,O5M&)[V_\*F&QN.&H6)KX;+R_6+Y*^&)_
M\9ODA'_<R??<R>OFA$M>ZGWAZW3KVU2_Z71>_%[!6GA\XY<K]G1M;WLS.:]H
MU5^)\Y>^J/=+ZFASK?-0VW\*YVNWK6>$@>FKO0=?O]K[@\3AO0<%G)Y'7%IX
M9^0M?M%J6MCZ:]1.D!SCT>CL$>9RDZJE9K44(T6%DRY5IEW4H[JS;*8,3"J;
M)X41N?GVTYJ'4E+3$-6_A75;7_4%Y6DY WBCL.YA2*>T<2H+=5PU#JNJJ;CB
MI@L[>EFKPM@#S&'WLYE(#<=PV8&B5BX?0_0&'/XHZ9#'C\/2,<PMH.]'Y5;M
M3]07YL'4UX%6AOF>JNF>*E%/^GQ/^L&N%C-'Y;*6L 4=.!>6?% AV@/52?M*
M4ODZ5:#4\6?4/.]R&=;Y>:@,.I./F708 P<^#@6X8W_4]W;C&A:.)CZFTM*P
M:D5Y/I6TTBD[?4[5K@,9Y*6XY^!-+ >AXV4S._I>KK2-&D%J; \-W:9"5!$>
M?8=?=BK:P78D!-,-AGE!9:U(C*03(;#9Y\"=P,X>AD+B3]"1(4-N*XLJ;9F<
M>,*CBM>!<"VR$R2J+]2TYI8*6/&2%];'93,IW;_O2I53-'TJW_.HON^-RI^>
MW6%OA#J(#H*T. (#3<;YNG@R594483&LI8[U\6_"WHB9";Y,1%8NA$1XG(7J
MD(U-'0&V[:K&N]=??&)$7 HJ3.1=4(4U ?*]:_2ZT2M6]@_VJM&*_'LEDPY]
M-45XC),$#,&V>I#<C$Z]>.\B?DJM*L:*&R<L\3V"%M7<O9O2U;>K(RW0\<(G
MX7G#="SQ_P%02P$"% ,4    " #&,$Y;R"FMH"T#  #]"P  $
M    @ $     <WEN+3(P,C4Q,#$S+GAS9%!+ 0(4 Q0    ( ,8P3EL@^]8D
M_0H  '^&   4              "  5L#  !S>6XM,C R-3$P,3-?;&%B+GAM
M;%!+ 0(4 Q0    ( ,8P3EL6PI"B7@<  .=7   4              "  8H.
M  !S>6XM,C R-3$P,3-?<')E+GAM;%!+ 0(4 Q0    ( ,8P3ENQ&?/)IAP
M   5 0 2              "  1H6  !T;3(U,C@U-3AD,5\X:RYH=&U02P$"
M% ,4    " #&,$Y;24;=PZX-  "^.P  %@              @ 'P,@  =&TR
M-3(X-34X9#%?97@Y.2TQ+FAT;5!+ 0(4 Q0    ( ,8P3EL-&(OW: T  )U8
M   6              "  =)   !T;3(U,C@U-3AD,5]E>#DY+3(N:'1M4$L%
3!@     &  8 B@$  &Y.      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2528558d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20251013.xsd" xlink:type="simple"/>
    <context id="AsOf2025-10-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2025-10-13</startDate>
            <endDate>2025-10-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-10-13" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-10-13" id="Fact000004">0000894158</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-10-13" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-10-13" id="Fact000010">2025-10-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-10-13" id="Fact000011">THERIVA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-10-13" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-10-13" id="Fact000013">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-10-13" id="Fact000014">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-10-13" id="Fact000015">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-10-13" id="Fact000016">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-10-13" id="Fact000017">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-10-13" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-10-13" id="Fact000019">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-10-13" id="Fact000020">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-10-13" id="Fact000021">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-10-13" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-10-13" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-10-13" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-10-13" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-10-13" id="Fact000026">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-10-13" id="Fact000027">TOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-10-13" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-10-13" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
